TERT and melanoma: Altogether, given that adaptive therapeutic strategies are required to overcome acquired resistance in BRAFV600 melanoma patients, we believe that our findings will have relevant clinical implications for patient management and that TERT promoter mutation detection should be considered to better anticipate patient relapse and introduction of immunotherapy.